CSIMarket Company Name, Ticker, Suppliers, else..
 
Capricor Therapeutics inc   (NASDAQ: CAPR)
 

Capricor Therapeutics Inc's Suppliers Performance

CAPR's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
CAPR Costs vs Sales of Suppliers Growth

• More on CAPR Suppliers






Capricor Therapeutics Inc's Comment on Supply Chain


The company depends on raw materials essential for producing its product candidates and may rely on third-party manufacturers to increase manufacturing capacity for advanced clinical trials and potential commercialization. Risks include limited manufacturing capacity, challenges in scaling manufacturing processes, compliance with current Good Manufacturing Practice (cGMP) regulations, retention of manufacturing personnel, and obtaining FDA approval for manufacturing processes and facilities. The company maintains relationships with licensors, collaborators, and third parties, notably relying on Nippon Shinyaku to fulfill obligations under U.S. and Japan Distribution Agreements and to commercialize Deramiocel for the treatment of Duchenne Muscular Dystrophy (DMD). Nippon Shinyaku is the only supplier specifically named.

Capricor Therapeutics Inc's Comment on Supply Chain


The company depends on raw materials essential for producing its product candidates and may rely on third-party manufacturers to increase manufacturing capacity for advanced clinical trials and potential commercialization. Risks include limited manufacturing capacity, challenges in scaling manufacturing processes, compliance with current Good Manufacturing Practice (cGMP) regulations, retention of manufacturing personnel, and obtaining FDA approval for manufacturing processes and facilities. The company maintains relationships with licensors, collaborators, and third parties, notably relying on Nippon Shinyaku to fulfill obligations under U.S. and Japan Distribution Agreements and to commercialize Deramiocel for the treatment of Duchenne Muscular Dystrophy (DMD). Nippon Shinyaku is the only supplier specifically named.







CAPR's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Capricor Therapeutics inc 520.35 22.27 -114.59 231
SUBTOTAL 0.00 0.00 0.00 -


Sources: Capricor Therapeutics inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Capricor Therapeutics inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.